Amir London assumed responsibility as Kamada’s CEO in July 2015.
Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience.
Prior to joining Kamada , Mr. London was the COO of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as home-care solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publicly-traded operations management consulting firm, responsible for the firm’s global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.
Chaime Orlev is serving as our Chief Financial Officer since December 2017. Prior to joining us, he served as Chief Financial Officer and VP Finance and Administration of Bioblast Pharma Ltd (NASDAQ:ORPN) from 2016 to 2017. Prior to that, Mr. Orlev served in various finance positions, in the biotech industry, including VP Finance and Administration of Chiasma Inc. (NASDAQ: CHMA), Chief Financial Officer of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), and Chief Financial Officer of Gammacan Inc. Mr. Orlev also served as VP Finance and Chief Financial Officer of Huntleigh USA Corporation. Mr. Orlev received his M.B.A. from the Leon Recanati Graduate School of Business Administration at the Tel Aviv University and a B.A. in Business Administration from the College of Business in Israel. Mr. Orlev is a Certified Public Accountant under the laws of the state of Israel.
Dr. Stein brings over 15 years of experience in the healthcare industry, including 12 years in increasingly senior positions at multi-national pharmaceutical companies in Israel. Prior to joining Kamada, she served for four years as Medical Director at Sanofi. In this position, Dr. Stein led the medical affairs and pharmacovigilance departments of the Israeli unit of the company, overseeing all aspects of product life-cycle management. From 2009 through 2013, Dr. Stein held multiple positions of increasing responsibility at Merck Sharp & Dohme, including Pharmacovigilance Country Lead, Medical & Scientific Liaisons Team Leader and Medical Affairs Manager, with expertise in vaccines, women’s health and HIV. From 2005 through 2009, she served as Medical Affairs Manager, with expertise in oncology, at Roche Pharmaceuticals. Prior to that, from 2001 through 2005, Dr. Stein was a practicing physician in Israel, first at Rabin Medical Center, Belinson Campus, and then at Schneider Children’s Medical Center.
Dr. Stein holds an M.D. from the Tel-Aviv Sackler Faculty of Medicine
Dr. Ayalon serves as our Vice President of Research & Development since February 2019.
Dr. Ayalon has nearly 20 years of experience in drug discovery and drug development, as a senior biopharmaceuticals executive. Prior to joining Kamada, Dr. Ayalon served as Head of R&D at 89bio Ltd., where she led the overall development strategy of the company and managed all R&D functions, including medical, clinical, pre-clinical, CMC, regulatory, and project management. Previously, Dr. Ayalon was a Project Champion at Teva Pharmaceutical Industries Ltd.. She was also Vice President of Research & Development at Galmed Pharmaceuticals Ltd.. Prior to this, Dr. Ayalon held various R&D positions in biopharmaceutical companies.
Dr. Ayalon holds a Ph.D. in cell biology from Tel-Aviv University, and holds a PostDoc in Molecular Biology of the Cell from the Weizmann Institute of Science.
Eran Nir serves as our VP Operations since November 2016. Mr. Nir has over 14 years of operation management experience in the pharmaceutical and medical industries. His recent roles include management of TEVA’s Pharmaceutical plant in Jerusalem, VP Operations of Emilia Cosmetics and management of a medical equipment plant of Philips Medical Systems. Mr. Nir’s extensive experience spans across the management of large scale FDA and EMA- approved manufacturing facilities, tech-transfer of new products from development to production and the implementation of world-class operational excellence systems.
Mr. Nir has B.SC degree in Industrial Engineering and M.B.A. both from Ben Gurion University.
Yael Brenner has served as our Vice President Quality since March 2015. Mrs. Yael Brenner has experience of more than 20 years in Quality Management, including QA and QC managerial positions in the pharmaceutical industry. Prior to her joining Kamada, her last position in Teva Pharmaceuticals Industries was Senior Director Quality Operations of Teva Kfar Saba Site, managing over 400 workers in QA, QC and RA. Mrs. Brenner holds B.Sc. and M.Sc. degrees in Chemistry from the Technion, Haifa, and in addition Certified Quality Engineer (CQE) from the American and the Israeli and Societies for Quality.
Ariella Raban serves as Kamada’s Vice President, Human Resources since May 2018.
Mrs. Raban joined Kamada in March 2014 and served as Human Resources Manager for Kamada’s manufacturing site. Mrs. Raban has more than a decade of expertise in different positions in the field of HR in the pharmaceutical industry.
Prior to joining us, she served as a Human Resources Manager at Teva Pharmaceuticals.
Mrs. Raban holds a BA degree in Humanities Social Science from Ben-Gurion University.
Orit Pinchuk has served as our Vice President, Regulatory Affairs since October, 2014. Mrs. Pinchuk has experience of more than 20 years in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of Regulatory Affairs and Compliance. Prior to her joining Kamada, her last positions in Teva Pharmaceuticals Industries were Director of Compliance and RA, Operation IL and Sr. Director RA, R&D and Operation IL. She has extensive experience with FDA, EMA and CANADA Health Authorities.
Mrs. Pinchuk holds B.Tech. in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. in Applied Chemistry from Jerusalem Hebrew University.
Dr. Tov served in both active hospital academic and clinical positions at Bnai Zion Medical Center, Haifa, Israel. He specializes in Internal, Pulmonary and Sleep Medicine and served as Head of the Pulmonary Unit, and as Deputy of Internal Ward C, at Bnei Zion Medical Center, for 14 years. During these years, Dr. Tov served in academia and held appointments at the Bruce Rappoport School of Medicine-Technion in Haifa, Israel.
Dr. Tov is a member of the American Thoracic Society and the European Respiratory Society. He holds an M.D. and a Ph.D. from the Bruce Rappoport School of Medicine-Technion.
Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry.
Prior to joining Kamada, Mr. Kyiet served as Chief Operating Officer of PolyPid, a clinical-stage emerging biopharmaceutical company. Earlier in his career, he was Director, Worldwide Supply Chain, at Biosense Webster (a Johnson & Johnson company), a leader in the diagnosis and treatment of heart arrhythmias. Prior to this, Mr. Kyiet served as Director, Global Strategic Operations and Alliances, for Lumenis, Ltd., a leading medical equipment and laser device manufacturer. He began his career practicing corporate law, both as in-house counsel and as a Partner at Amit, Pollak, Matalon & Co.
Mr. Kyiet is a graduate of the Haifa University Faculty of Law in Israel, where he received a LL.B degree. He also earned an Executive M.B.A. from the Haifa Graduate Business School.
Leon Recanati has served on our board of directors since May 2005 and has served as Chairman since March 7, 2013. Mr. Recanati currently serves as a board member of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange. He is also a board member of the following private companies: GlenRock Israel Ltd., GlenRock Medical, Shellcase, Gov, Govli Financial Services Ltd., Govli Limited, Microbes Inc., RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Fund and Newbank Ltd. He is currently Chairman and Chief Executive Officer of GlenRock. Previously, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an MBA degree from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.
David Tsur is the Co-founder of Kamada and served has our Chief Executive Officer and on our board of directors since the company’s inception in 1990 until July 2015. Currently he serves as our Active Deputy Chairman of the Board. Prior to co-founding Kamada, Mr. Tsur was Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur holds a BA degree in Economics and International Relations and an MBA in Business Management from the Hebrew University of Jerusalem.
Mr. Avraham Berger has served on our board of directors since August 2016. Mr. Berger currently serves as technology investor. Until 2014, Mr. Berger served as a senior partner and chief executive officer of PwC Israel, for more than 20 years. Mr. Berger joined PwC Israel in 1976 and led it from 1991. Mr. Berger has vast experience in mergers and acquisitions and complex public offerings, both in Israel and abroad. Mr. Berger lectures at professional forums and has published several articles in the professional press. Mr. Berger also serves as Chairman of the board of directors of TopAudio Ltd. and serves as director on the board of Weizmann Institute of Science. Mr. Berger holds a Bachelor’s degree in Accounting and Economics awarded from Tel Aviv University and is a certified public accountant in Israel.
Dr. Michael Berelowitz has served on our Board of Directors since July 2015. Dr. Berelowitz currently serves as a biopharmaceuticals consultant, and is a member of several Boards of Directors or Scientific Advisory Boards, including, Oramed Pharmaceuticals (NASDAQ: ORMP), Recro Pharma, Inc. (NASDAQ: REPH) and DIR Technologies. Dr. Berelowitz has more than 40 years’ experience in clinical development and academic research, including 15 years of experience in pharmaceutical development with Pfizer, Inc. where he served as a Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit. Prior to that, Dr. Berelowitz spent a number of years in academia and has held several appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine. In Addition, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society and has chaired the Task Force on Research of the New York State Council on Diabetes.
Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town.
Jonathan Hahn has served on our board of directors since March 2010. He is currently the President and a director of Tuteur. Previously, Mr. Hahn held a business development position in Forest Laboratories, Inc., based in New York. Mr. Hahn holds a BA degree from San Andrés University and an MBA degree from New York University — Stern School of Business, with specializations in Finance and Entrepreneurship.
Shmuel (Milky) Rubinstein has served an external director of Clal Biotechnology Industries Ltd since February 17, 2011. In addition, Mr. Rubinstein currently serves on the board of the directors of several companies, including Exalenz Breathtaking Solutions Ltd, since 2008, Medison Biotech Ltd, since 2011, Trima Pharma Ltd, since 2015, and Sol-Gel Ltd since 2016. Mr. Rubinstein served as the Chairman of the board of directors of Tiltan Pharma Ltd from 2015 until June 2017. Mr. Rubinstein served as the Chief Executive Officer and General Manager at Taro Pharmaceuticals Industries Ltd (NYSE:TARO) from 1990 to 2010. Mr. Rubinstein also acts as a consultant to several companies, including startup companies and BDO. In 2003, Mr. Rubinstein received the Industry Award from the Manufacturers Association of Israel.
Prof. Itzhak Krinsky, Ph.D, has broad-based expertise in the pharmaceutical industry, years of experience in investment banking, and a distinguished academic career in finance and business economics. Prof. Krinsky developed extensive knowledge of the pharmaceutical industry during his 12 years of working at Teva Pharmaceutical Industries Ltd, from which he retired earlier this year. During his tenure at Teva, Prof. Krinsky served as Executive Vice President, Corporate Business Development, a member of the Teva Executive Committee, Chairman of Teva Japan, Chairman of Teva South Korea, and Head of Business Development Asia Pacific. Prior to joining Teva, he held various senior positions in investment banks in New York City, including with Bankers Trust, Deutsche Bank, and the Silverfern Group, Inc. Before his career on Wall Street, Prof. Krinsky was a Professor of Finance and Business Economics at the Michael G. DeGroote School of Business, McMaster University, Ontario, Canada. Prof. Krinsky has published more than 80 articles in leading peer reviewed academic journals. Prof. Krinsky currently serves as a director at following companies: Wavelength Pharmaceuticals, since October 2017, Halo Pharmaceutical, Inc, since June 2017, Concordia International Corp, since May 2017, Achellos Therapeutics, since April 2017 and Exodos Life Sciences Limited Partnership, since April 2017. In 2014, Prof. Krinsky was named by SCRIP as one of the top 100 Global Leaders in the Pharmaceutical Industry. Prof. Krinsky received Bachelor’s and Master’s degrees in Economics from Tel Aviv University and a Ph.D. in Economics from McMaster University in Canada.
Asaf Frumerman is a partner at Brosh Capital Partners L.P. Mr. Frumerman worked as an analyst at The Dragon Variation Fund. Mr. Frumerman holds a B.A in Accounting & L.L.B, from the College of Management.
Efrat Makov serves as a director of BioLight Life Sciences Ltd. (TASE: BOLT) (formerly Bio Light Israeli Life Sciences Investments Ltd.), an emerging global ophthalmic company, since April 2011. Ms. Makov also serves as a director of Anchiano Therapeutics Ltd. (TASE: ANCN) (formerly BioCanCell Ltd.), a clinical-stage biopharmaceutical company. Ms. Makov served as the Chief Financial Officer of Alvarion Ltd. (formerly NASDAQ; TASE: ALVR), a global provider of autonomous Wi-Fi networks, from April 2007 to December 2010. Ms. Makov served as the Chief Financial Officer of Aladdin Knowledge Systems Ltd. (formerly NASDAQ; TASE: ALDN) (n/k/a Safenet, Inc.), an information security leader specializing in authentication, software DRM and content security, from September 2005 to January 2007, where she was responsible for the finance, operations, information systems and human resources functions. Prior to that, Ms. Makov served in management positions at two Israeli-based public companies, including as Vice President of Finance at Check Point Software Technologies Ltd. (NASDAQ: CHKP), a worldwide leader in IT security, from September 2002 to August 2005. Ms. Makov served as Director of Finance for NUR Macroprinters Ltd. (formerly NASDAQ: NURM) (n/k/a Ellomay Capital), from August 2000 to August 2002. Prior to that, Ms. Makov spent seven years in public accounting with Arthur Andersen LLP in its New York, London and Tel Aviv offices. Ms. Makov holds a B.A. degree in Accounting and Economics from Tel Aviv University and is a certified public accountant in Israel and the United States.